JP2006519842A - アザスピラン化合物による癌治療法 - Google Patents

アザスピラン化合物による癌治療法 Download PDF

Info

Publication number
JP2006519842A
JP2006519842A JP2006506985A JP2006506985A JP2006519842A JP 2006519842 A JP2006519842 A JP 2006519842A JP 2006506985 A JP2006506985 A JP 2006506985A JP 2006506985 A JP2006506985 A JP 2006506985A JP 2006519842 A JP2006519842 A JP 2006519842A
Authority
JP
Japan
Prior art keywords
cancer
hydrogen atom
unbranched
carbon atoms
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006506985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519842A5 (enExample
Inventor
ドナルド・エイチ・ピッカー
ジェフリー・ダブリュー・ヘンソン
サイモン・フリッカー
クンワル・シャイルバイ
ゲイリー・エス・ジェイコブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Callisto Pharmaceuticals Inc
Original Assignee
Callisto Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Callisto Pharmaceuticals Inc filed Critical Callisto Pharmaceuticals Inc
Publication of JP2006519842A publication Critical patent/JP2006519842A/ja
Publication of JP2006519842A5 publication Critical patent/JP2006519842A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
JP2006506985A 2003-03-10 2004-03-10 アザスピラン化合物による癌治療法 Withdrawn JP2006519842A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45295103P 2003-03-10 2003-03-10
US47492903P 2003-06-03 2003-06-03
PCT/US2004/007144 WO2004080408A2 (en) 2003-03-10 2004-03-10 Method of treating cancer with azaspirane compositions

Publications (2)

Publication Number Publication Date
JP2006519842A true JP2006519842A (ja) 2006-08-31
JP2006519842A5 JP2006519842A5 (enExample) 2007-06-14

Family

ID=32994468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006506985A Withdrawn JP2006519842A (ja) 2003-03-10 2004-03-10 アザスピラン化合物による癌治療法

Country Status (7)

Country Link
US (2) US20070015780A1 (enExample)
EP (1) EP1610806A4 (enExample)
JP (1) JP2006519842A (enExample)
CA (1) CA2518357A1 (enExample)
MX (1) MXPA05009708A (enExample)
TW (1) TW200505438A (enExample)
WO (1) WO2004080408A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200707258B (en) * 2005-03-24 2008-06-25 Thromb X N V Novel anti-PLGF antibody
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
JP2010523579A (ja) * 2007-04-02 2010-07-15 インスティテュート フォア ワンワールド ヘルス Ｃｆｔｒ阻害剤化合物およびそれらの使用
CA2699454C (en) * 2007-08-27 2012-07-24 Auxagen, Inc. Methods for inhibiting tgf-.beta.
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2010033507A1 (en) * 2008-09-16 2010-03-25 St. Louis University Method of enhancing tgf-beta signalling
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US20100267706A1 (en) * 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
DK2543812T3 (en) * 2011-07-08 2015-01-26 Welltec As Hydraulic well pump

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
US6051596A (en) * 1990-08-10 2000-04-18 Anormed, Inc. Immunosuppressive compositions
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
IL118815A (en) * 1995-07-13 2000-06-29 Anormed Inc N,N-diethyl-8,8-dipropyl-2-azaspiro¬4.5¾decane-2-propanamine dimaleate and pharmaceutical compositions comprising it
US5939450A (en) * 1995-07-13 1999-08-17 Anormed Inc. N,N-dimethyl-8,8-dipropyl-2-azaspiro 4.5!decane-2-propanamine dimaleate
CZ367598A3 (cs) * 1996-05-17 1999-05-12 Anormed Inc. Použití substituovaného azaspiranu

Also Published As

Publication number Publication date
MXPA05009708A (es) 2006-05-25
TW200505438A (en) 2005-02-16
EP1610806A4 (en) 2006-04-19
CA2518357A1 (en) 2004-09-23
US20070015780A1 (en) 2007-01-18
US20050250801A1 (en) 2005-11-10
WO2004080408A3 (en) 2004-12-09
WO2004080408A2 (en) 2004-09-23
EP1610806A2 (en) 2006-01-04

Similar Documents

Publication Publication Date Title
US9421208B2 (en) Methods for the treatment of solid tumors
JP2021046418A (ja) コルテキソロン１７α−バレレートを含む腫瘍治療に用いるための組成物
KR20190006948A (ko) Tg02를 사용한 암의 치료
JP2006519842A (ja) アザスピラン化合物による癌治療法
PH12015500246B1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
CA2404087A1 (en) Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
JP2006519842A5 (enExample)
CA2238283C (en) Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
BR112021011699A2 (pt) Terapia de combinação com um inibidor de raf e um inibidor de cdk4/6 para uso no tratamento contra câncer
US20090259054A1 (en) Methods and Compositions for the Treatment of Angiogenesis and Macular Degeneration
KR20210060642A (ko) 성장 관련 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
CA3019682A1 (en) Treatment of renal cell carcinoma with lenvatinib and everolimus
Kauntz Cellular and molecular targets of silibinin, a natural flavonoid, in colorectal cancer prevention and therapy
Murphy et al. Human pancreatic acinar cells have functional cholecystokinin receptors
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
Keller et al. 13C-MIXED TRIGLYCERIDE BREATH TEST (13C-MTG) DEMONSTRATES SUPERIORITY OF ENTERIC COATED MONOLITHIC ENZYME PREPARATION OVER PLACEBO: A MULTICENTRE, DOUBLE BLIND, PLACEBO CONTROLLED CROSS-OVER TRIAL
Iki et al. Somatostatin cell hyperplasia in the pancreas
Zarantonello et al. Volatile organic compounds in breath in patients with pancreatic tumor. A preliminary case-control prospective study
Funakoshi et al. Final results of a phase II study of S-1 in patients with metastatic pancreatic cancer
Pezzilli et al. Exhaled breath analysis in chronic pancreatitis
Dominguez-Munoz et al. Oral pancreatic enzyme substitution therapy in patients with chronic pancreatitis: Assuring a normal nutritional status
Schmitz-Winnenthal et al. Selective expression of tumor associated antigens by samples derived from human pancreatic cancer
Viterbo et al. REGULATION OF PANCREATITIS-ASSOCIATED PROTEIN (PAP) INDUCED CYTOKINE EXPRESSION THROUGH SIGNAL TRANSDUCTION PATHWAYS NFKB, JNK, AND ERK
Iglesias-García et al. Impact of endoscopic ultrasound (EUS)-guided fine needle biopsy in the diagnosis of pancreatic masses
Sung et al. Acute biliary pancreatitis in cholecystectomized patients

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070423

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090818